Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers
about
Epigenetics of colorectal cancerEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeEpithelial-Mesenchymal Transition and Breast CancerEpigenetic treatment of solid tumours: a review of clinical trialsEpigenome-based personalized medicine in human cancerAdvancements in the delivery of epigenetic drugsPhase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsInterplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approachesPhase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.Chromatin remodeling, cell proliferation and cell death in valproic acid-treated HeLa cellsA double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Targeting DNA methylation for epigenetic therapy.Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell lineEpigenetics across the human lifespan.Different effects of valproic acid on photoreceptor loss in Rd1 and Rd10 retinal degeneration micePhase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group reportCurrent and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Interpreting clinical assays for histone deacetylase inhibitors.Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancerZebularine suppresses TGF-beta-induced lens epithelial cell-myofibroblast transdifferentiation by inhibiting MeCP2.Effects of a novel DNA methyltransferase inhibitor Zebularine on human lens epithelial cells.Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.DNA Hypomethylation Contributes to Genomic Instability and Intestinal Cancer Initiation.Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.Targeting DNA methylation.DNA methylation and cancer pathways in gastrointestinal tumors.Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experienceEpigenetic modifications as therapeutic targets.Role of epigenomics in ovarian and endometrial cancers.Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers.Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.Epigenetic-based therapies in cancer: progress to date.Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.Epigenetics and oncology.Canonical and new generation anticancer drugs also target energy metabolism.Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
P2860
Q24598045-2BE16D6C-F800-4BA7-B1C9-DD4463AA7970Q24608659-4EBD3FFF-BE15-47AD-9ED0-4CB1847CE085Q24632949-58D6287B-8484-4226-AC70-4298A9D812DAQ26773055-6A67CCA7-1243-445B-86DC-69DEE85BF82DQ26773803-8E0CE21A-BF3F-440B-94E1-C0F2B7C90FC4Q28083951-B3A19BE0-1531-45DE-B475-6AF9CE937EA3Q28088478-C34CB79D-4CA7-446D-B82D-1438C4B1D496Q33393266-9A8D5686-DB6E-4CE9-96DD-BF46006913CBQ33404975-E04F5633-518A-4AA8-9C44-7B52D0DCD8CBQ33752772-C8589190-BDF4-4946-A659-5F89CDBA1EC1Q33835913-AA66D25C-F4E3-4CEF-89D2-27D89A13BBFEQ34107482-BB2A18FE-A284-449B-832F-276F5FB5F055Q34113695-B3F4AC49-26F8-4639-9349-3A1F35790261Q34142430-01F11072-A899-4469-93AA-6C9CC7C46D08Q34171631-181B010F-3E69-4E8D-9157-3036FF71DD62Q34258037-D0765A7C-79E3-47A7-807E-A7AEA992C3F5Q34366588-E4F54969-7F12-480C-A21B-1CCCD67ABE38Q34391404-8EF6EC4B-E20F-433B-85BE-7292EA9CCE12Q34476181-563B3918-2285-4DA2-91A3-65A8D6522AE2Q34722045-97A87843-870B-44F8-BD8F-72F2F59974DFQ35000789-239034F1-DB19-4462-A749-062E86573986Q35003657-2CC039A9-EC83-4C1E-A722-64FF94F9693AQ35079955-63CDDDFD-64F1-4ECE-83EA-BC79CA3CB743Q35531772-73C40660-2C2A-42AF-B109-2BA33C093A18Q35673407-14E78F3F-8D1F-4118-A057-35D7F0CF11CAQ35964716-FB024209-393B-4C56-82CC-6D200226D517Q37059820-2FD3E173-266A-4887-BF05-E5FA7A00870FQ37257390-9074737F-5EA4-443D-8F06-4A09097CA735Q37320354-57A070C9-57E9-43C0-95C2-6DDD7600B335Q37346219-AA6EE25A-1125-47B8-8607-3625605F54A9Q37417441-9DEA0279-1653-48F0-B93B-196FD0ACA79AQ37800011-9F1A64A1-E1D2-4D51-8DA7-298A6EB14EFBQ37961734-DB1D610D-6133-4C19-93A3-EF5C184E7454Q37962013-89A4416E-C178-42C1-9AC0-1DF4A963B0D5Q37962016-76262E49-52AB-41DD-9EB7-56BAEF0B1E0FQ37964702-1307A8A8-B23D-4D92-A0C1-AD68FA28F37DQ38121995-07BF11E1-57BA-47FB-9F21-347AD671D45CQ38195260-9DB24AFD-21A4-465A-97BE-CFFDCDD964B7Q38208982-CC19D923-4D8A-4ABD-B736-32AC7DEE06C3Q38542620-CBD23751-CA04-4982-9492-EA5C447EEB15
P2860
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase I study of epigenetic mo ...... patients with advanced cancers
@ast
Phase I study of epigenetic mo ...... patients with advanced cancers
@en
type
label
Phase I study of epigenetic mo ...... patients with advanced cancers
@ast
Phase I study of epigenetic mo ...... patients with advanced cancers
@en
prefLabel
Phase I study of epigenetic mo ...... patients with advanced cancers
@ast
Phase I study of epigenetic mo ...... patients with advanced cancers
@en
P2093
P2860
P1476
Phase I study of epigenetic mo ...... patients with advanced cancers
@en
P2093
Andres O Soriano
David Hong
Fadi Braiteh
Johannes Wolff
Leandro De Padua Silva
Marcella M Johnson
Stefanie Alexander
P2860
P304
P356
10.1158/1078-0432.CCR-08-1247
P407
P577
2008-10-01T00:00:00Z